CompanyGraphAt a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleMarket cap is $1.88B, above the global median of $1.15B
- PositionReturn on equity is 19%, higher than 95% of its Pharmaceutical Retailers peers (median 8.7%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.10%Below 5Y avg (1.49%)
Annual Rate
ZAR 0.32Paid semi-annual
Payout Ratio
50.2%Sustainable
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
30.04BZAR1.88B · vs all stocks (USD)
Trailing P/E
25.68xvs Pharmaceutical Retailers peers
Revenue (TTM)
42.83BZAR2.68B · vs all stocks (USD)
Profit Margin
2.29%vs Pharmaceutical Retailers peers
Beta
0.3050xvs all stocks
52-Week Change
-15.38%vs all stocks
Forward Annual Dividend Yield
1.10%vs all stocks
Market Capitalization
30.04BZAR1.88B · vs all stocks (USD)
Enterprise Value
30.10BZAR1.88B · vs all stocks (USD)
Trailing P/E
25.68xvs Pharmaceutical Retailers peers
Forward P/E
16.73xvs Pharmaceutical Retailers peers
Price to Sales (TTM)
0.5853xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
4.44xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.7340xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
13.70xvs Pharmaceutical Retailers peers
Profit Margin
2.29%vs Pharmaceutical Retailers peers
Operating Margin
3.38%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
5.79%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
18.96%vs Pharmaceutical Retailers peers
Revenue (TTM)
42.83BZAR2.68B · vs all stocks (USD)
Revenue per Share (TTM)
49.97ZARUpdated Aug 21, 2026Quarterly Revenue Growth
9.90%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
9.41BZAR588.00M · vs all stocks (USD)
EBITDA (TTM)
3.21BZAR200.50M · vs all stocks (USD)
Net Income (TTM)
978.89MZAR61.17M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-42.60%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
1.79BZAR112.03M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
978.89MZAR61.17M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3184ZARUpdated Aug 21, 2026Forward Annual Dividend Yield
1.10%vs all stocks
Trailing Annual Dividend Rate
0.4534ZARUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.56%vs all stocks
5-Year Average Dividend Yield
1.49%vs all stocks
Payout Ratio
50.19%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
49.45MZARFY2026 · Feb 28, 2026Revenue
42.83BZARFY2026 · Feb 28, 2026Cost of Goods Sold
33.42BZARFY2026 · Feb 28, 2026Gross Profit
9.41BZARFY2026 · Feb 28, 2026Operating Income
-1.80BZAR-112.64M · vs all stocks (USD)
Pre-tax Income
1.39BZARFY2026 · Feb 28, 2026Income Tax Expense
359.11MZARFY2026 · Feb 28, 2026Net Income
1.04BZARFY2026 · Feb 28, 2026EBIT
1.95BZARFY2026 · Feb 28, 2026EBITDA (Income Statement)
3.21BZARFY2026 · Feb 28, 2026Selling, General & Administrative
1.44BZARFY2026 · Feb 28, 2026Other Operating Expenses
7.60BZARFY2026 · Feb 28, 2026Non-operating Interest Income
46.24MZARFY2026 · Feb 28, 2026Non-operating Interest Expense
553.98MZARFY2026 · Feb 28, 2026Minority Interests (P&L)
-56.72MZARFY2026 · Feb 28, 2026Preferred Stock Dividends
0.00ZARFY2026 · Feb 28, 2026Operating Cash Flow
1.36BZARFY2026 · Feb 28, 2026Free Cash Flow
267.99MZARFY2026 · Feb 28, 2026Cash & Cash Equivalents (End of Period)
-1.17BZARFY2026 · Feb 28, 2026Starting Profit (CF Statement)
1.39BZARFY2026 · Feb 28, 2026Stock-based Compensation
35.34MZARFY2026 · Feb 28, 2026Other Non-cash Items
458.59MZARFY2026 · Feb 28, 2026Change in Accounts Receivable (CF)
-530.62MZARFY2026 · Feb 28, 2026Change in Other Assets/Liabilities
-1.34MZARFY2026 · Feb 28, 2026Capital Expenditures
-1.09BZARFY2026 · Feb 28, 2026Net Acquisitions
-183.12MZARFY2026 · Feb 28, 2026Purchase of Investments
0.00ZARFY2026 · Feb 28, 2026Net Investing Cash Flow
-1.27BZARFY2026 · Feb 28, 2026Long-term Debt Issuance
628.89MZARFY2026 · Feb 28, 2026Long-term Debt Payments
-849.04MZARFY2026 · Feb 28, 2026Common Stock Repurchase
-60.43MZARFY2026 · Feb 28, 2026Other Financing Charges
-22.01MZARFY2026 · Feb 28, 2026Net Financing Cash Flow
-302.58MZARFY2026 · Feb 28, 2026Shares Outstanding
856.11MSharesUpdated Aug 21, 2026Float Shares
563.22MSharesUpdated Aug 21, 2026% Held by Insiders
39.19%vs all stocks
% Held by Institutions
61.70%vs all stocks
Total Cash (MRQ)
499.76MZAR31.23M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5840ZARUpdated Aug 21, 2026Total Debt (MRQ)
6.64BZAR414.79M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.17xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
1.11xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
6.59ZARUpdated Aug 21, 2026Total Assets
20.74BZAR1.30B · vs all stocks (USD)
Total Current Assets
12.34BZARFY2026 · Feb 28, 2026Total Liabilities
15.04BZARFY2026 · Feb 28, 2026Total Non-current Assets
8.40BZARFY2026 · Feb 28, 2026Total Non-current Liabilities
3.88BZARFY2026 · Feb 28, 2026Total Current Liabilities
11.16BZARFY2026 · Feb 28, 2026Cash
499.76MZARFY2026 · Feb 28, 2026Cash & Cash Equivalents
499.76MZARFY2026 · Feb 28, 2026Accounts Receivable
1.88BZARFY2026 · Feb 28, 2026Inventory
7.91BZARFY2026 · Feb 28, 2026Accounts Payable
6.98BZARFY2026 · Feb 28, 2026Short-term Debt
2.88BZARFY2026 · Feb 28, 2026Long-term Debt
3.76BZARFY2026 · Feb 28, 2026Common Stock (Book)
6.16BZARFY2026 · Feb 28, 2026Retained Earnings
4.18BZARFY2026 · Feb 28, 2026Total Shareholders' Equity
5.69BZAR355.84M · vs all stocks (USD)
Treasury Stock
3.75BZARFY2026 · Feb 28, 202652-Week Low
2.89KZACUpdated Aug 21, 202652-Week High
3.90KZACUpdated Aug 21, 202652-Week Change
-15.38%vs all stocks
Beta
0.3050xvs all stocks
50-Day MA
3.17KZACUpdated Aug 21, 2026200-Day MA
3.47KZACUpdated Aug 21, 2026Avg 10-Day Volume
484.93KSharesUpdated Aug 21, 2026Avg 30-Day Volume
831.06KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.14ZARUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 19%, higher than 95% of its Pharmaceutical Retailers peers (median 8.7%)Significant
Return on equity: 0.19Industry median: 0.09Industry P95: 0.17Peers compared: 29.00
Financial Health
Altman Z-Score 3.92: safe zoneNotable
Altman Z-Score: 3.92
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Market cap is $1.88B, above the global median of $1.15BNotable
Market cap (USD): 1,877,057,502.56Global Median: 1,146,734,693.424
Revenue is $2.68B, above the global median of $520.53MNotable
Revenue (USD): 2,676,268,456.284Global Median: 520,528,949.311
Levered free cash flow is $61.17M, above the global median of $16.24MNotable
Levered free cash flow (USD): 61,173,043.848Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Waigaoqiao Free Trade Zone Development Co., Ltd.
Tier 1FlowUnit ReplicationProductionInterface
Weis Markets Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
Grupo Mateus S.A.
Tier 1FlowUnit ReplicationInterfaceProduction
Trial Holdings Inc.
Tier 1FlowUnit ReplicationRiskInterface
Prosegur Compañía de Seguridad, S.A.
Tier 1FlowUnit ReplicationRuleProduction
BGF Retail Co. Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Eternal Asia Supply Chain Co., Ltd.
Tier 1FlowUnit ReplicationProductionSenseMaking
Shenzhen Aisidi Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceRisk
Ingles Markets Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
Sendas Distribuidora S.A.
Tier 1FlowUnit ReplicationProductionInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Tomy Company Ltd.
3 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover
Polycab India Ltd.
3 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover
Precision Wires India Ltd.
3 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover